FOXO4-DRI Preclinical Evidence and Translational Challenges: From Mouse Models to Clinical Reality
Summary
FOXO4-DRI has been studied in human cell cultures and several mouse models beyond the original 2017 Cell paper. Examples include chondrocytes, keloid fibroblasts, endothelial cells, Leydig-cell dysfunction and pulmonary fibrosis. Results are context-dependent: a pulmonary-hypertension model reported harm. These experiments do not establish human safety, pharmacokinetics or an effective dose; the October 14, 2026 searches identified no human treatment trial.
Key Data
Human cells outside the body and mouse models
Examples below are not an exhaustive study or laboratory count
Includes the cell-penetrating segment
FOXO4-DRI worsened hemodynamics in a mouse model
The Landmark 2017 Cell Study: Methods and Findings
Baar et al. (2017; PMID 28340339) combined human fibroblast experiments with doxorubicin, accelerated-aging and naturally aged mouse models. The illustrated systemic protocols used 5 mg/kg on three alternate days (days 1, 3 and 5), intravenously in the doxorubicin arm and intraperitoneally in specified aging experiments. Later readouts, including renal markers at 30 days, should not be confused with continuous dosing.
The study reported changes in senescence-associated markers, activity, fur and renal outcomes. These varied by model and endpoint; they do not support a single tissue-wide percentage of senescent-cell clearance.
Follow-Up Studies Across Different Models
Follow-up studies extend beyond the two tissue types described in early summaries. Examples include expanded healthy-donor human chondrocytes (PMID 33996787), aged-mouse Leydig-cell dysfunction (PMID 31959736), bleomycin-induced mouse pulmonary fibrosis (PMID 35510614; PMID 37074394), keloid fibroblasts and organ cultures (PMID 39994346), and endothelial cultures plus mouse vascular-aging experiments (PMID 41625068). These are different experiments, not replications of every original outcome.
Huang et al. reduced senescence-associated cells without improving chondrogenic potential. Born et al. found worsened pulmonary hemodynamics and endothelial-cell loss with FOXO4-DRI in a serotonin-transporter-overexpressing mouse model (PMID 36515093). The direction of an effect depends on tissue and disease context.
Evidence Gaps for Clinical Translation
The trial status review records the search scope and its limits. Publicly accessible preclinical reports do not provide a validated human exposure–response relationship, elimination half-life or safe dose. D-peptide design and delayed biological effects cannot substitute for pharmacokinetic measurements.
Manufacturing a defined 46-residue D-peptide, establishing an appropriate formulation and route, and evaluating dose-related and long-term toxicity remain development questions. The absence of a published result is not proof that no unpublished development work exists.
Where FOXO4-DRI Fits in the Senolytic Clinical Pipeline
Human senolytic research includes drugs other than FOXO4-DRI. For example, Farr et al. tested dasatinib plus quercetin in a randomized trial in postmenopausal women (PMID 38956196); the primary bone-resorption endpoint was negative overall, with exploratory subgroup findings. Such trials establish evidence for their own interventions and populations, not for FOXO4-DRI.
Open Questions for FOXO4-DRI Translation
Open questions include human exposure, dose response, long-term effects on tumor biology and tissue repair, immunogenicity, and the effects of repeated treatment. Senescence is a growth-arrest state with both beneficial and harmful functions; killing senescent cells does not simply release those same cells to divide again.
The mouse pulmonary-hypertension finding illustrates why changes in senescence markers alone cannot establish a favorable clinical risk–benefit balance.
Frequently Asked Questions
Has later work extended beyond chondrocytes and Leydig cells?
Yes. Published examples include pulmonary fibrosis, keloid fibroblasts and endothelial cell/vascular-aging models. This is a list of examples, not a count of independent laboratories or a systematic inventory.
Is the evidence uniformly beneficial?
No. A pulmonary-hypertension study reported worse pulmonary hemodynamics and endothelial-cell loss with FOXO4-DRI in mice. Benefits reported in other models cannot establish general safety.
Does activity in human cells establish a human treatment effect?
No. Cultures lack the absorption, distribution, metabolism, immune responses and organ interactions of a living person. Human treatment trials are needed to establish clinical outcomes.
Has FOXO4-DRI been studied in humans?
The October 14, 2026 ClinicalTrials.gov searches for FOXO4-DRI, FOXO4 DRI and Proxofim found no matching study. PubMed searches and primary-paper review did not identify a human treatment trial. Human fibroblast, chondrocyte and endothelial culture studies are preclinical evidence. The search cannot exclude every unregistered or differently named study worldwide.
Citations
Effects of Intermittent Senolytic Therapy on Bone Metabolism in Postmenopausal Women: A Phase 2 Randomized Controlled Trial
Farr JN, Atkinson EJ, Achenbach SJ, et al.
Nature Medicine (2024)
Randomized trial of dasatinib plus quercetin in 60 postmenopausal women. The primary bone-resorption endpoint was negative overall; exploratory subgroup findings require further testing. This is not a FOXO4-DRI trial.
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, et al.
Cell (2017)
Original human-fibroblast and mouse experiments. Illustrated protocols used three alternate-day 5 mg/kg injections, intravenously in the doxorubicin arm and intraperitoneally in specified aging experiments. Later outcomes are follow-up, not continuous dosing or plasma pharmacokinetics.
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, Lin H
Frontiers in Bioengineering and Biotechnology (2021)
Expanded healthy-donor chondrocyte cultures showed reduced senescence-associated cells but no improvement in chondrogenic potential.
FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Han X, Yuan T, Zhang J, et al.
Journal of Cellular and Molecular Medicine (2022)
FOXO4-DRI reduced fibrosis-associated endpoints in a bleomycin mouse model; the experimental comparison with pirfenidone does not establish clinical equivalence.
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Kong YX, Li ZS, Liu YB, et al.
Communications Biology (2025)
Human keloid fibroblast and organ-culture experiments used 25 micromolar FOXO4-DRI for three days. Organ cultures were followed through day 10; follow-up does not establish continuous treatment or sustained apoptosis.
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Hu Z, Li F, Hu C, et al.
Frontiers in Bioengineering and Biotechnology (2025)
Human endothelial cell experiments and naturally aged/D-galactose-treated mice; animal methods report 5 mg/kg intraperitoneally every two days for one month or four weeks, respectively.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, et al.
Circulation (2023)
FOXO4-DRI worsened pulmonary hemodynamics and endothelial-cell loss in serotonin-transporter-overexpressing mice; other interventions were tested in additional rodent models.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.